Epix terminates depression drug development
Pharmaceutical Business Review: "Epix Pharmaceuticals has reported that the company is discontinuing clinical development of PRX-00023 due to lack of significant efficacy shown in the recently completed Phase IIb trial in patients with major depressive disorder."
3 comments:
Its nice to see that company is discounting a clinical development due to major depressive disorder.. Good thing.. Continue..
=====
james
Dual Diagnosis
I think the company is doing well.
I am eager to know more about this topic.
Kindly help with more web links related to this topic.
Hi
This blog is very nice. From here you can search different drugs by giving their names or by giving desciption about the diseases. So it's good to have these types of sites.
Post a Comment